🇺🇸 FDA
Patent

US 10913946

RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy

granted A61PA61P21/00A61P43/00

Quick answer

US patent 10913946 (RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy) held by BIOMARIN TECHNOLOGIES B.V. expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN TECHNOLOGIES B.V.
Grant date
Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61P, A61P21/00, A61P43/00